Samsung Biologics Partners with Kurma for Biologics Development and Manufacturing

Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, recently announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.

Samsung Biologics will provide CMC (chemistry, manufacturing, and control) services to streamline the gene-to-IND (investigational new drug) process for Kurma Partners' portfolio companies, accelerating clinical development with its advanced facilities and expertise.

John Rim, President and CEO of Samsung Biologics commented, “With our in-depth knowledge on effective scale-up strategy and a diverse portfolio of proprietary platform technologies, we are looking forward to providing robust CMC solutions to reduce uncertainties, ensure regulatory compliance, and ultimately maximize manufacturing efficiency for our clients.”

“We are very excited to partner with Samsung Biologics, a world-leading CDMO with capabilities of highest industry standards. This will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologics from discovery to the market.” said Daniel Parera, Partner at Kurma Partners. 

This agreement highlights Samsung Biologics' eagerness to work with emerging biotech firms in drug development and manufacturing while expanding its presence in key sectors in the U.S. and European markets.

Samsung Biologics and Kurma Partners announce strategic partnership for...
Samsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma’s portfolio companies. © Samsung Biologics

Company

Kurma Partners

24 rue Royale, 5e etage
75008 Paris
France

Company contact







Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.